Sigyn Therapeutics, Inc.

What they do

Sigyn Therapeutics develops extracorporeal blood purification medical devices. Its lead candidate, Sigyn CardioDialysis (formerly Sigyn Therapy), aims to reduce inflammatory molecules and cholesterol-transporting lipoproteins to lower Major Adverse Cardiovascular Events. The pipeline also includes cancer therapies: ImmunePrep, ChemoPrep, and ChemoPure, designed to enhance drug delivery and reduce chemotherapy toxicity. The company has no approved products and generates no revenue from operations.

Revenue drivers

• No commercial products — The company is development-stage with no approved or marketed devices; reported revenues in recent years were minimal (e.g., $143,322 in 2019, and nominal quarterly amounts thereafter).
• Convertible debt and equity financings — Funding comes from convertible debentures and preferred stock exchanges; recent transactions include issuing 2,704 Series B preferred shares as inducements in June 2025.

Recent performance

For the nine months ended September 30, 2025, the company reported total assets of $135,571, total liabilities of $6.1 million, and shareholder equity of negative $5.9 million. Cash and equivalents were $85,571 as of that date. Long-term debt stood at $3.5 million. The company recorded a net loss of $3.3 million for 2024 and $4.1 million in 2023, with negative operating cash flows each year (2024: -$872,436).

Strategy

Management shifted the lead candidate's focus from infectious disease to cardiovascular disease, filing a trademark for CardioDialysis in November 2025. The company believes this opens a larger market opportunity and eases patient enrollment for pivotal FDA studies versus prior sepsis and viral indications. It also positions the technology for the dialysis industry, where most patients die from cardiovascular events. The pipeline retains cancer therapies as downstream opportunities.

Risks

• Going concern risk — The company has negative working capital, minimal cash ($85,571 as of September 30, 2025), and recurring operating losses, raising substantial doubt about its ability to continue as a going concern.
• Regulatory and clinical risk — CardioDialysis is in early development with no approved device or completed pivotal trials; FDA approval is uncertain and would require significant clinical evidence.
• Dilution risk — The company relies on convertible debt and preferred stock, with conversion features that can lead to substantial dilution of existing shareholders (e.g., 2,704 preferred shares issued as inducements in 2025).
• Dependence on key personnel — The company's progress depends on its CEO and a small team that previously developed an Ebola device, but key-person risk is high and executive changes were disclosed in 2025.

Outlook

Management plans to advance CardioDialysis into first-in-human studies, initially targeting end-stage renal disease patients with endotoxemia and inflammation, though the latest focus is cardiovascular disease. They view the dialysis market as a primary opportunity, citing large players like Fresenius and DaVita. The company continues to seek financing to fund operations and development, but no specific timeline or funding commitments are disclosed.